| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO)
GLAXO Technical Analysis
1.5
| As on 24th Apr 2024 GLAXO SHARE Price closed @ 2077.25 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1695.78 & Sell for SHORT-TERM with Stoploss of 2081.66 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GLAXOSHARE Price
| Open | 1956.50 | Change | Price | % |
| High | 2087.00 | 1 Day | 130.50 | 6.70 |
| Low | 1954.25 | 1 Week | 178.45 | 9.40 |
| Close | 2077.25 | 1 Month | 114.20 | 5.82 |
| Volume | 278853 | 1 Year | 829.40 | 66.47 |
| 52 Week High 1696.10 | 52 Week Low 1230.60 | ||||
NSE INDIA Most Active Stocks
| IDEA | 13.10 | -9.03% |
| SAIL | 164.65 | 8.14% |
| YESBANK | 25.45 | -0.78% |
| TATASTEEL | 165.55 | 2.73% |
| IRFC | 149.00 | 0.85% |
| SOUTHBANK | 29.10 | 1.04% |
| MRPL | 248.70 | 10.75% |
| SUZLON | 41.80 | -0.12% |
| BEL | 236.50 | 0.92% |
| RAMASTEEL | 14.00 | 2.56% |
NSE INDIA Top Gainers Stocks
| ROML | 63.05 | 19.98% |
| COMPUSOFT | 35.20 | 19.93% |
| SHRADHA | 78.55 | 19.83% |
| STEELCITY | 102.95 | 19.78% |
| WEIZMANIND | 142.25 | 19.59% |
| TEMBO | 240.90 | 18.61% |
| CHENNPETRO | 1075.00 | 15.82% |
| YUKEN | 1180.65 | 13.81% |
| ORIENTCEM | 230.50 | 12.85% |
| AEGISCHEM | 604.50 | 12.41% |
NSE INDIA Top Losers Stocks
| GLAXO Daily Charts |
GLAXO Intraday Charts |
Whats New @ Bazaartrend |
GLAXO Free Analysis |
|
|
GLAXO Important Levels Intraday
| RESISTANCE | 2333.06 |
| RESISTANCE | 2251.02 |
| RESISTANCE | 2200.31 |
| RESISTANCE | 2149.60 |
| SUPPORT | 2004.90 |
| SUPPORT | 1954.19 |
| SUPPORT | 1903.48 |
| SUPPORT | 1821.44 |
GLAXO Target April 2024
| 4th UP Target | 2981.39 |
| 3rd UP Target | 2713.83 |
| 2nd UP Target | 2548.44 |
| 1st UP Target | 2383.06 |
| 1st DOWN Target | 1911.14 |
| 2nd DOWN Target | 1745.76 |
| 3rd DOWN Target | 1580.37 |
| 4th DOWN Target | 1312.81 |
GLAXO Weekly Target
| 4th UP Target | 2049.16 |
| 3rd UP Target | 1992.09 |
| 2nd UP Target | 1956.81 |
| 1st UP Target | 1921.53 |
| 1st DOWN Target | 1820.87 |
| 2nd DOWN Target | 1785.59 |
| 3rd DOWN Target | 1750.31 |
| 4th DOWN Target | 1693.24 |
GLAXO Target2024
| 4th UP Target | 3308.71 |
| 3rd UP Target | 2856.34 |
| 2nd UP Target | 2576.71 |
| 1st UP Target | 2297.09 |
| 1st DOWN Target | 1499.21 |
| 2nd DOWN Target | 1219.59 |
| 3rd DOWN Target | 939.96 |
| 4th DOWN Target | 487.59 |
GlaxoSmithKline Pharmaceuticals Limited ( NSE INDIA Symbol : GLAXO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GLAXO Synopsis Technicals View
| 50 Day EMA |
Close is Above EMA 50 (Short Term) |
Bullish | |
| 100 Day EMA | Close is Above EMA 100 (Mid Term) | Bullish | |
| 200 Day EMA | Close is Above EMA 200 (Long Term) | Bullish | |
| MACD (12 26 9) | MACD Line is Grater Then SIGNAL Line | Bullish | |
| RSI (14) | RSI is 34.21 | Sideways | |
| MFI (14) | MFI is 21.49 | Sideways | |
| CCI (20) | CCI is Below -100 | Over Sold | |
| WILLIAM %R (14) | William %R is -33.43 | Sideways | |
| ADX (14) | ADX is Above 20 & +DI is Below -DI | Down Trend | |
| PSAR | Stoploss For Long Buy | 1272.81 | |
| 10 Day Avg Volume | Traded -25.30 % Less then 10 Day Average Volume | ||
GLAXO Other Details
| Segment | EQ | |
| Market Capital | 250729365504.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-General | |
| Offical website | > | |
GLAXO Address
 |
||
GLAXO Latest News
GLAXO Business Profile
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, gastrointestinal, nutrition, dermatology, respiratory, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Betnovate, Calpol, Ceftum, and Synflorix brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India. Address: GSK House, Mumbai, India, 400030
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service